Analysis of the reasons why the condition worsens after taking Vigabatrin (Ocoda)

Vigabatrin (Vigabatrin) is a γ-Aminobutyric acid (GABA) transaminase inhibitor, through irreversible inhibition of GABA decomposition enzyme, increases the concentration of GABA in the central nervous system, thereby enhancing inhibitory nerve conduction and achieving anti-epileptic effects. Commonly used for refractory epilepsy and infantile spasms. Its efficacy depends on the sensitivity of neurons to GABA levels. However, due to its strong mechanism of action, improper use may aggravate the condition.

Some patients' condition worsens after taking Vigabatrin, which is often related to excessive dosage or improper medication regimen . Excessive use can cause excessive nervous system depression, which may occur drowsiness, impaired movement coordination, or an increased frequency of epileptiform seizures. In addition, sudden discontinuation of medication or unreasonable dosage adjustment may also cause rebound epilepsy and aggravate the condition.

Each patient's tolerance to Vigabatrin varies. Some patients may have abnormal drug metabolism or GABAsensitivity, resulting in excessively high blood drug concentrations or unstable drug efficacy, thereby aggravating epileptic symptoms. Patients with renal insufficiency or combined use of other central nervous system depressant drugs may also increase the risk of adverse reactions and make their condition fluctuate significantly.

In order to avoid worsening of the condition, clinical practice should be strict Follow the doctor's prescribed dosage, gradually adjust the medication, and regularly monitor blood drug concentration and epileptic seizures. If increased seizure frequency or neurological side effects occur, the dose should be adjusted promptly or combined with other anti-epileptic drugs. Through individualized treatment and standardized management, most patients can safely use Vigabatrin and achieve stable therapeutic effects.

Reference link:https://www.drugs.com